A Review on Mitochondrial Dysfunction and Oxidative stress due to Complex-Ⅰ in Parkinson Disease

V Nuthan Kumar Babu; Navneet Khurana

doi:10.52711/2321-5836.2021.00031

Research Journal of Pharmacology and Pharmacodynamics

ISSN

2321-5836 (Online)
0975-4407 (Print)

Submit Article

A Review on Mitochondrial Dysfunction and Oxidative stress due to Complex-Ⅰ in Parkinson Disease

Author(s): V Nuthan Kumar Babu, Navneet Khurana

Email(s): Email ID Not Available

DOI: 10.52711/2321-5836.2021.00031

Address: V Nuthan Kumar Babu, Dr. Navneet Khurana*
Department of Pharmacology, Lovely professional University, Jalandhar-Delhi G.T. Road, Phagwara, Punjab (India)-144411.
*Corresponding Author

Published In: Volume - 13, Issue - 4, Year - 2021

View HTML

View PDF

ABSTRACT:
Parkinson’s disease (PD) is the common physical movement disorder, and it is 2nd most progressive widespread neurodegenerative disorder all over the world, and it is reported that and essential 10 million, over 0.3 % of the total world population. A thoughtful reduction of the neurotransmitter dopamine (DA) in the striatum is the main cause of these motor symptoms, collectively known as parkinsonism. Mitochondria serves as most important organelle in most of the cells and are essential for life and it is also called as heart for all cellular metabolisms. The main and most important role of mitochondria is generation of ATP via oxidative phosphorylation. In this study will study about how complex ? deficiency effects the mitochondrial and oxidative stress and reactive oxygen species which cause mitochondrial dysfunction and we also study emerging therapies for Parkinson disease with the help of coenzyme Q10 and some genes like FUN-14, FUNDC-1 and dimethyl fumarate or BG-12 in some phases of clinical trials and also by cell transplantation therapy and in future this study helps in finding how this sporadic Parkinson disease occurs in parkinsonism.

Keywords:

Cite this article:
V Nuthan Kumar Babu, Navneet Khurana. A Review on Mitochondrial Dysfunction and Oxidative stress due to Complex-Ⅰ in Parkinson Disease. Research Journal of Pharmacology and Pharmacodynamics. 2021;13(4):167-0. doi: 10.52711/2321-5836.2021.00031

Cite(Electronic):
V Nuthan Kumar Babu, Navneet Khurana. A Review on Mitochondrial Dysfunction and Oxidative stress due to Complex-Ⅰ in Parkinson Disease. Research Journal of Pharmacology and Pharmacodynamics. 2021;13(4):167-0. doi: 10.52711/2321-5836.2021.00031 Available on: https://rjppd.org/AbstractView.aspx?PID=2021-13-4-10

REFERENCE:
1.   Sudhakar Raja Subramaniam, Marie-Francoise Chesselet et. al. Mitochondrial dysfunction and oxidative stress in Parkinson disease. Prog Neurobiol Jul-Aug 2013;106-107:17-32
2.   David N. Hauser, Teresa G. Hastings et.al, Mitochondrial dysfunction and oxidative stress in Parkinson's disease and monogenic parkinsonism. Neurobiol Dis. 2013 Mar; 51:35-4
3.   Anindita Bose and M. Flint Beal Mitochondrial dysfunction in Parkinson’s disease. April-July2016;13731
4.   Jin-Sung Park and Ryan L. Davis and Carolyn M. Sue Mitochondrial Dysfunction in Parkinson’s Disease: New Mechanistic Insights and Therapeutic Perspectives. Curr Neurol Neurosci Rep-2018;18(5):21
5.   Florian J. Bock and Stephen W. G. Tait, Mitochondria as multifaceted regulators of cell death. Nat Rev Mol Cell Biol. 2020 Feb;21(2):85-100
6.   Debapriya Garabadu, Nidhi Agrawal, Anjali Sharma and Sahil Sharma Mitochondrial metabolism: a common link between neuroinflammation and neurodegeneration. Behav Pharmacol. 2019 Dec;30(8):642-652
7.   S. B. Larsen1 and Z. Hanss1 and R. Krüger1,2 The genetic architecture of mitochondrial dysfunction in Parkinson’s disease. Cell Tissue Res. 2018 Jul;373(1):21-3
8.   Nicole Exner1, Anne Kathrin Lutz2,3, Christian Haass1,3 and Konstanze F Winklhofer Mitochondrial-dysfunction in Parkinson disease: molecular mechanisms and pathophysiological consequences. EMBO J. 2012 Jul 18; 31(14): 3038–3062.
9.   Panchanan Maiti, Jayeeta Manna and Gary L. Dunbar Current understanding of the molecular mechanisms in Parkinson's disease: Targets for potential treatments. Transl Neurodegener. 2017 Oct 25;6:28.
10.   Irene H. Flønes, Erika Fernandez‑Vizarra, Maria Lykouri, Brage Brakedal, Geir Olve Skeie, Hrvoje Miletic, Peer K. Lilleng, Guido Alves, Ole‑Bjorn Tysnes, Kristoffer Haugarvoll, Christian Dölle, Massimo Zeviani, Charalampos Tzoulis, Neuronal complex I deficiency occurs throughout the Parkinson’s disease brain, but is not associated with neurodegeneration or mitochondrial DNA damage. Acta Neuropathol. 2018 Mar; 135(3):409-425.
11.   Zheng, B., et al., 2010. PGC-1alpha, A Potential therapeutic target for early Intervention in Parkinson's disease. Sci Transl Med. 2010 Oct 6;2(52):52ra73.
12.   Kukat, C., et al., 2011. Super-resolution microscopy reveals that mammalian mitochondrial nucleoids have a uniform size and frequently contain a single copy of mtDNA. Proc Natl Acad Sci U S. 2011 Aug 16;108(33):13534-9.
13.   Emily M. Rocha, Briana DeMiranda, Laurie H. Sanders, Alpha-synuclein: Pathology, mitochondrial dysfunction and neuroinflammation in Parkinson’s disease. Neurobiol Dis. 2018 Jan; 109(Pt B):249-257.
14.   Bobby Thomas and M. Flint Beal. Mitochondrial Therapies for Parkinson’s Disease. Mov Disord. 2010;25 Suppl 1(Suppl 1):S155-60.
15.   Cristofol Vives-Bauzaa, Rosa L.A. de Vriesa, Maja Aleksandra Tocilescua, Serge Przedborski, Is there a pathogenic role for mitochondria in Parkinson’s disease. Trends Mol Med. 2011 Mar;17(3):158-65.
16.   Karuppagounder SS, Brahmachari S, Lee Y, Dawson VL, DawsonTM, Ko HS. The c-Abl inhibitor, nilotinib, protects dopaminergic neurons in a preclinical animal model of Parkinson’s disease. Sci Rep. 2014; 4:4874.
17.   Linker RA, Gold R. Dimethyl fumarate for treatment of multiple sclerosis: mechanism of action, effectiveness, and side effects. Curr Neurol Neurosci Rep. 2013; 13(11):394.
18.   Goodarzi P, Aghayan HR, Larijani B, Soleimani M, Dehpour AR, Sahebjam M, Ghaderi F, Arjmand B. Stem cell-based approach for the treatment of Parkinson’s disease. Med J Islam Repub Iran. 2015; 29:168.